I will be the first to admit that for us to truly understand health disparity, we will need to understand the core issues-such as the poor social structures-that drive people toward poor health. When we develop models to test whether a particular gene is going to contribute disproportionally to disease risk within a certain group, we must make sure that we also capture those things in the environment that may be as or even more important than genetic factors.
What kind of information do you collect?
We collect demographic and migrational information from our study participants, including Africans and African-Americans. This information enables us to develop models to test how 'old' genes from Africa work in new environments such as the United States to increase our risk for diseases or to protect us from getting certain diseases. We also collect information on diet and data relating to education and income. But I would say that most of the very critical factors in term of health disparity are things to do with social structure, the communities where people live, and social factors such as racism. These are extremely difficult factors for a setup like ours to fully capture. But there are other groups we intend to collaborate with who can help address such questions.
You once said, "The only way we can get to the meaning of human genetic variation is by removing racial classification in biomedical research." Can you please explain?
If we continue to label ourselves with racial terms, then we risk imposing racial perspective, consciously or otherwise, on the genome that does not necessarily hold. I never look at African-Americans from a genetic point of view as a uniform group. The only definition of African-American that I have that I can consistently defend is that these are descendents of the inhumane slave trade. That's it. And that's a social definition. At the genetic level, I think all bets are off, and the evidence that we continue to acquire shows that we are not studying a uniform group. African-Americans have ancestry from Africa, Europe, North America and Asia, among others. The combinations of these ancestries vary from person to person and from family to family.
You have criticized the FDA's decision to license the heart drug BiDil exclusively to African-Americans.
First, and most importantly there was no genetics in the study that led to its approval in African-Americans. The authors only considered whether people who self-identified as African-American responded to the drug. Second, I thought that in this instance the FDA was sending the wrong message to the community. For a very long time in human existence, most of the drugs that were used on all human populations were mostly developed and tested on white European males. Now what kind of a statement does a nation like the United States make to its people when it says, "We tested this drug on African-Americans and not on other members of society and it is therefore not good enough to treat members of other ethnic groups?" Clearly, there is a genetic or environmental reason why some people respond to the drug-we need to find out what that is. Some European-Americans, for instance, are likely to benefit from BiDil. To label it as an African-American or even a black drug, to me, is really just doing an otherwise effective drug a disservice.
Many researchers have complained of difficulties in enrolling minorities in clinical trials. Do you come across that problem in your research?
No, we do not. I always maintain that if you approach people well-if you approach people correctly, with the right sentiments, and if you indicate to them why it is important to participate in studies, people respond. We have now close to 3,000 African-American participants in our studies of complex diseases.
What have you learned that other people could apply if they want more minorities in their trials?
Employ members of that community on your staff. Go to churches, make presentations about the study and interact with community leaders who can advise you. One of the things I say to my staff is, you are going to run into the issue of people saying things like "Tuskegee experiments," and I say, "Do not run away from it." You have to confront it. You have to explain to people and tell people that because of that experience, we have to be extremely critical, but that should not prevent them from participating.
One of your missions is to increase training opportunities at NIH for minority scientists and scientists from developing nations. What are some of the barriers to minority participation in science?
There is this issue of exposure, and then there is the issue of good mentorship. We can provide mentorship, and we can provide exposure. For instance, our researchers have developed programs that [educate] high-school students, and we have invited them to spend time in our lab when I was at Howard University [where he previously headed the school's National Human Genome Center]. I intend to continue these types of programs [….] at NIH.
Some people have expressed concern that by studying genetics, you may be drawing attention to the least important factors contributing to health disparities. What do you say to your critics?
There are people who are extremely sensitive to hearing 'health disparity' and 'genomics' in the same sentence. It makes some people very uncomfortable, because people feel very strongly that you may take away from the most serious issues causing health disparities, such as social factors. What I tell them is that genomics is just one piece of the puzzle. It's a small piece of the puzzle. But I think given how genetics underlies our most important health issues, we need to study it. Human diversity at both the genetic and social levels is not an illusion: We need to embrace it; we need to understand it, and, more importantly, we need to interpret it correctly.
